

=> file caplus  
FILE 'CAPLUS' ENTERED AT 10:42:53 ON 18 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 May 2006 VOL 144 ISS 21  
FILE LAST UPDATED: 16 May 2006 (20060516/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>  
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> file registry  
FILE 'REGISTRY' ENTERED AT 10:43:04 ON 18 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 MAY 2006 HIGHEST RN 884586-69-0  
DICTIONARY FILE UPDATES: 16 MAY 2006 HIGHEST RN 884586-69-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.


\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information

NAME)

Absolute stereochemistry.



L20 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:131938 CAPLUS

DOCUMENT NUMBER: 144:247600

TITLE: Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats

AUTHOR(S): Dhalla, Arvinder K.; Wong, Mei-Yee; Wang, Wei-Qun; Biaggioni, Italo; Belardinelli, Luiz

CORPORATE SOURCE: Department of Pharmacology, CV Therapeutics, Palo Alto, CA, USA

SOURCE: Journal of Pharmacology and Experimental Therapeutics (2006), 316(2), 695-702

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Adenosine-induced tachycardia is suggested to be mediated via A2A receptors; however, the exact mechanism for this effect remains to be understood. The present study was carried out using regadenoson, a selective A2A adenosine receptor agonist, to determine the role of the A2A receptor subtype in adenosine-induced tachycardia. Regadenoson (0.3-50 µg/kg) given as a rapid i.v. bolus to awake rats caused a dose-dependent increase in heart rate (HR). Mean arterial pressure (MAP) increased at lower doses, whereas at higher doses, there was a decrease in MAP. The increase in HR was evident at the lowest dose (0.3 µg/kg) of regadenoson at which there was no appreciable decrease in MAP. Pretreatment with 30 µg/kg ZM 241385, an A2A receptor antagonist, attenuated the decrease in MAP and the increase in HR caused by regadenoson. Pretreatment with metoprolol (1 mg/kg), a β-blocker, attenuated the increase in HR but had no effect on the hypotension caused by regadenoson. In the presence of hexamethonium (10 mg/kg), a ganglionic blocker, the tachycardia was completely prevented even though MAP was further reduced. Regadenoson treatment (10 µg/kg) significantly increased plasma norepinephrine levels almost 2-fold above baseline. The dissociation of HR and MAP effects by dose, time, and pharmacol. interventions provides evidence that tachycardia caused by regadenoson is independent of the decrease in MAP and may not entirely be baroreflex-mediated, suggesting that regadenoson may cause a direct stimulation of the sympathetic nervous system via activation of A2A adenosine receptors.

IT 313348-27-5, Regadenoson

RL: PAC (Pharmacological activity); BIOL (Biological study)

presence of reversible hypoperfusion was 86%. The 400- $\mu$ g dose was better tolerated. Overall, regadenoson was well-tolerated; side effects (e.g., chest discomfort, flushing, dyspnea) were generally mild in severity and self-limiting. High-grade atrioventricular block and bronchospasm were not observed. Conclusions: Regadenoson is well-tolerated and seems as effective as adenosine for detecting and quantifying the extent of hypoperfusion observed with SPECT perfusion imaging. Phase III clin. trials are now underway, given the promise of regadenoson's reduced side effects and simplicity of bolus administration.

IT 313348-27-5, Regadenoson


RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)

(A2A adenosine receptor agonist regadenoson with 400- $\mu$ g dose combined with SPECT myocardial perfusion imaging was well-tolerated, effective with mild side effects for detecting reversible myocardial hypoperfusion in ischemia patient)

RN 313348-27-5 CAPLUS

CN Adenosine, 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:146593 CAPLUS

DOCUMENT NUMBER: 142:347942

TITLE: Regadenoson: Adenosine A2A agonist adjunct for myocardial perfusion imaging

AUTHOR(S): Sorbera, L. A.; Castaner, J.; Leeson, P. A.

CORPORATE SOURCE: Prous Science, Barcelona, 08080, Spain

SOURCE: Drugs of the Future (2004), 29(10), 998-1002

CODEN: DRFUD4; ISSN: 0377-8282

PUBLISHER: Prous Science

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Coronary vasodilators such as adenosine and dipyridamole, commonly used in pharmacol. stress testing, stimulate adenosine A2A receptors. However, both agents also nonselectively stimulate A1, A2B and A3 receptor subtypes, resulting in a high incidence of adverse events. Research efforts continue in an attempt to develop novel pharmacol. stress agents with fewer unwanted side effects, more selective A2A receptor-agonist effects and which can be administered as a bolus instead, of by infusion to produce selective vasodilatation with a rapid onset and short duration of action. Regadenoson is a novel low-affinity A2A

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

## PRIORITY APPLN. INFO.:

US 2002-399176P P 20020729  
 US 2002-399177P P 20020729  
 US 2002-426902P P 20021115  
 US 2003-459803P P 20030402  
 US 2003-629386 A2 20030729

AB A myocardial imaging method that is accomplished by administering one or more adenosine A2a adenosine receptor agonist to a human undergoing myocardial imaging as well as pharmaceutical compns. comprising at least one A2a receptor agonist, at least one liquid carrier, and at least one co-solvent. CVT-3146 is a useful pharmacol. stress agent for myocardial perfusion imaging. CVT-3146 is formulated in a liquid carrier comprising sodium chloride, sodium bicarbonate, EDTA, methylboronic acid and propylene glycol. It is administered as an i.v. bolus.

IT 313350-86-6, CVT 3033


RL: DGN (Diagnostic use); PAC (Pharmacological activity); BIOL (Biological study); USES (Uses)

(formulation of adenosine receptor agonists as pharmacol. stress agent for myocardial perfusion imaging)

RN 313350-86-6 CAPLUS

CN Adenosine, 2-(1-pentyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



CVT-3033

IT 313348-27-5, CVT 3146


RL: DGN (Diagnostic use); PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); BIOL (Biological study); PROC (Process); USES (Uses)

(formulation of adenosine receptor agonists as pharmacol. stress agent for myocardial perfusion imaging)

RN 313348-27-5 CAPLUS

CN Adenosine, 2-[4-[(methyamino)carbonyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:101001 --CAPLUS

DOCUMENT NUMBER: 140:141803

TITLE: Myocardial perfusion imaging using A2A receptor agonists

INVENTOR(S): Belardinelli, Luiz

PATENT ASSIGNEE(S): CV Therapeutics, Inc., USA

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004011010	A1	20040205	WO 2003-US23511	20030729
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492855	AA	20040205	CA 2003-2492855	20030729
AU 2003259264	A1	20040216	AU 2003-259264	20030729
EP 1524984	A1	20050427	EP 2003-771950	20030729
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1671399	A	20050921	CN 2003-817592	20030729
JP 2005538190	T2	20051215	JP 2005-505626	20030729
WO 2005082379	A1	20050909	WO 2004-US2304	20040127
WO 2005082379	C1	20060119		
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:875101 CAPLUS

DOCUMENT NUMBER: 139:358763

TITLE: Inhibition of platelet aggregation with glycoprotein IIb/IIIa receptor antagonist

INVENTOR(S): Porter, Stephen R.; Fitzgerald, Desmond Joseph

PATENT ASSIGNEE(S): VDDI Pharmaceuticals, USA

SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003090733	A1	20031106	WO 2003-US12515	20030423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003223702	A1	20031110	AU 2003-223702	20030423
PRIORITY APPLN. INFO.:			US 2002-374860P	P 20020423
			WO 2003-US12515	W 20030423

AB The present invention provides methods and compns. for preventing platelet aggregation and for treating individuals suffering from conditions or undergoing procedures that may result in unwanted platelet aggregation. In particular the invention provides methods and compns. for arterial vessel pacification. The methods are based on the administration of a therapeutically effective amount of a glycoprotein IIb/IIIa receptor antagonist, e.g., xemilofiban. The treatment may commence prior to a medical or surgical procedure or an outbreak of a condition, either of which results in the activation of platelets that may lead to thrombus formation, and may continue thereafter.

IT 313348-27-5, CVT 3146


RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);

US 2003-652378

A1 20030829

OTHER SOURCE(S):  
GI

MARPAT 139:323754



AB 2-Adenosine N-pyrazole compds. I wherein R1 is CH<sub>2</sub>OH, amide, R2 and R4 are H, alkyl, aryl, R3 is alkyl, halo, NO<sub>2</sub>, CN, ether, thio ether, amine, sulfone, sulfonamide, ester, and methods for using the compds. as A<sub>2</sub>A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart. Thus, I (R1 = OH, R2 = R4 = H, R3 = CO<sub>2</sub>Et) was prepared its affinity for the adenosine A<sub>2</sub>a receptor (K<sub>i</sub> = 10-1000 nM), is reported. All compds. show moderate selectivity for human A<sub>2</sub>A vs. A<sub>1</sub> receptor.

IT 313348-27-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nucleoside N-pyrazole as adenosine A<sub>2</sub>a receptor agonists for purposes of imaging the heart)

RN 313348-27-5 CAPLUS

CN Adenosine, 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT:

18

THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:92399 CAPLUS

DOCUMENT NUMBER: 138:131113

TITLE: Method and compositions using A2A adenosine receptor agonists and type IV phosphodiesterase inhibitors for treating the inflammatory response

INVENTOR(S): Linden, Joel M.; Sullivan, Gail W.; Scheld, W. Michael

PATENT ASSIGNEE(S): University of Virginia Patent Foundation, USA; University of Virginia

SOURCE: U.S., 22 pp., Cont.-in-part of U.S. Ser. No. 320.769, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6514949	B1	20030204	US 2000-634407	20000809
US 5877180	A	19990302	US 1994-272821	19940711

PRIORITY APPLN. INFO.:	APPLICATION NO.	DATE
	US 1994-272821	A2 19940711
	US 1998-3930	B2 19980108
	US 1999-320769	B2 19990527

OTHER SOURCE(S): MARPAT 138:131113

AB Agonists of A2A adenosine receptors, optionally in combination with a Type IV phosphodiesterase (PDE) inhibitor, are effective for the treatment of the inflammatory response of mammalian tissue.

IT 313348-27-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(A2A adenosine receptor agonist and type IV phosphodiesterase inhibitor for treating inflammatory response)

RN 313348-27-5 CAPLUS

CN Adenosine, 2-[4-[(methyamino)carbonyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



vasodilation during myocardial perfusion imaging for noninvasive detection of subcrit. arterial stenosis.

IT 313348-27-5, CVT 3146


RL: DGN (Diagnostic use); PAC (Pharmacological activity); BIOL (Biological study); USES (Uses)

(selective A2A adenosine receptor agonist CVT-3146 as a coronary vasodilator in conscious dogs: potential for use in myocardial perfusion imaging)

RN 313348-27-5 CAPLUS

CN Adenosine, 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

30

THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:732391 CAPLUS

DOCUMENT NUMBER: 138:362124

TITLE: Structure-affinity relationships of the affinity of 2-pyrazolyl adenosine analogues for the adenosine A2A receptor

AUTHOR(S): Pallo, Venkata P.; Elzein, Elfatih O.; Gothe, Scott A.; Li, Zhihe; Gao, Zhenhai; Meyer, Stephanie; Blackburn, Brent; Zablocki, Jeff A.

CORPORATE SOURCE: CV Therapeutics, Department of Bioorganic Chemistry, Palo Alto, CA, 94304, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(20), 2935-2939

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:362124

AB The structure-affinity relationships of two novel 2-substituted adenosine series containing a substituted pyrazole attached at the N-1 or C-4 position for the adenosine (ADO) A2A receptor are described. Comps. in the 2-(N-1-pyrazolyl) adenosine series provided the highest affinity for the ADO A2A receptor as compared to the 2-(C-4-pyrazolyl) series. The main structural differences between the two series point to the N-1 nitrogen imparting favorable binding interactions with the receptor.

IT 313348-27-5P 313350-86-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


AB CVT-3146, 2-(N-1-(4-N-methylcarboxamidopyrazolyl)) adenosine derivative and compound CVT-3033, 2-(4-(1-N-pentylpyrazolyl)) adenosine derivative, were found to be short acting functionally selective coronary vasodilators (CV t0.5 = 5.2±0.2 and 3.4±0.5 min, resp. - rat isolated heart 50% reversal time) with good potency (EC50S = 6.4±1.2 nM and 67.9±16.7 nM, resp.), but they possess low affinity for the ADO A2A receptor (Ki = 1122±323 nM and 2138±952 nM, resp.; pig striatum).

IT 313348-27-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (2-substituted PI system derivs. of adenosine as coronary vasodilators acting via A2A adenosine receptor)

RN 313348-27-5 CAPLUS

CN Adenosine, 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 313350-86-6  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (2-substituted PI system derivs. of adenosine as coronary vasodilators acting via A2A adenosine receptor)

RN 313350-86-6 CAPLUS


CN Adenosine, 2-(1-pentyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L20 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN



RN 313350-86-6 CAPLUS

CN Adenosine, 2-(1-pentyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:454277 CAPLUS

DOCUMENT NUMBER: 135:266911

TITLE: Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists

AUTHOR(S): Gao, Zhenhai; Li, Zhihe; Baker, Stephen P.; Lasley, Robert D.; Meyer, Stephanie; Elzein, Elfatih; Palle, Venkata; Zablocki, Jeff A.; Blackburn, Brent; Belardinelli, Luiz

CORPORATE SOURCE: Departments of Pharmacological Sciences, CV Therapeutics, Palo Alto, CA, USA

SOURCE: Journal of Pharmacology and Experimental Therapeutics (2001), 298(1), 209-218


CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Several potent and selective A2A adenosine receptor agonists are currently available. These compds. have a high affinity for the A2A receptor and a long duration of action. However, in situations where a short duration of action is desired, currently available A2A receptor agonists are less than ideal. From a series of recently synthesized A2A receptor agonists, two agonists (CVT-3146 and CVT-3033) with low affinity were selected for further characterization as selective and short-acting coronary



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:911270 CAPLUS

DOCUMENT NUMBER: 134:56921

TITLE: Preparation of nucleoside N-pyrazole as adenosine A2a receptor agonists for purposes of imaging the heart  
INVENTOR(S): Zablocki, Jeff A.; Elzein, Elfatih O.; Palle, Venkata P.

PATENT ASSIGNEE(S): CV Therapeutics, Inc., USA

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000078779	A2	20001228	WO 2000-US40281	20000621
WO 2000078779	A3	20010315		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6403567	B1	20020611	US 1999-338185	19990622
CA 2377746	AA	20001228	CA 2000-2377746	20000621
EP 1189916	A2	20020327	EP 2000-960112	20000621
EP 1189916	B1	20031210		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200200588	T2	20020923	TR 2002-200200588	20000621
JP 2003506461	T2	20030218	JP 2001-515876	20000621
AU 760806	B2	20030522	AU 2000-71324	20000621
AT 256141	E	20031215	AT 2000-960112	20000621
BR 2000011856	A	20040210	BR 2000-11856	20000621
PT 1189916	T	20040331	PT 2000-960112	20000621
NZ 516334	A	20040528	NZ 2000-516334	20000621
ES 2209974	T3	20040701	ES 2000-960112	20000621
TW 230161	B1	20050401	TW 2000-89112272	20000913



L20 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:911269 CAPLUS

DOCUMENT NUMBER: 134:56920

TITLE: Preparation of nucleoside C-pyrazole as adenosine A2a receptor agonists for purposes of imaging the heart  
 INVENTOR(S): Zablocki, Jeff A.; Elzein, Elfatih O.; Palle, Venkata P.

PATENT ASSIGNEE(S): CV Therapeutics, Inc., USA

SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000078778	A2	20001228	WO 2000-US17095	20000621
WO 2000078778	A3	20010510		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6214807	B1	20010410	US 1999-338327	19990622
CA 2375430	AA	20001228	CA 2000-2375430	20000621
CA 2375430	C	20060314		
EP 1192169	A2	20020403	EP 2000-943022	20000621
EP 1192169	B1	20030514		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200200320	T2	20020521	TR 2002-200200320	20000621
BR 2000011854	A	20020611	BR 2000-11854	20000621
JP 2003506460	T2	20030218	JP 2001-515875	20000621
AT 240341	E	20030515	AT 2000-943022	20000621
PT 1192169	T	20030930	PT 2000-943022	20000621
AU 766712	B2	20031023	AU 2000-57558	20000621
NZ 516335	A	20031031	NZ 2000-516335	20000621
ES 2193969	T3	20031116	ES 2000-943022	20000621
TW 589321	B	20040601	TW 2000-89112282	20000913



=>